A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 23667769
DCOM- 20130514
LR  - 20170220
IS  - 2150-5349 (Print)
IS  - 2150-5349 (Linking)
VI  - 4
IP  - 2
DP  - 2013 May 6
TI  - Management practices of hepatitis C virus infected alcoholic hepatitis patients: 
      A survey of physicians.
PG  - 16-22
LID - 10.4292/wjgpt.v4.i2.16 [doi]
AB  - AIM: To survey gastroenterologists and hepatologists regarding their current
      views on treating hepatitis C virus (HCV) infected alcoholic hepatitis (AH)
      patients. METHODS: A sixteen item questionnaire was electronically mailed to
      gastroenterologists and hepatologists. A reminder was sent after 2 mo to increase
      the response rate. Participation of respondents was confidential. Accessing
      secured web site to respond to the questionnaire was considered as informed
      consent. Responses received on the secured website were downloaded in an excel
      sheet for data analysis. RESULTS: Analyzing 416 responses to 1556 (27% response
      rate) emails, 57% respondents (56% gastroenterologists) reported HCV prevalence >
      20% amongst AH patients. Sixty nine percent often treated AH and 46% preferred
      corticosteroids (CS). Proportion of respondents with consensus (75% or more
      respondents agreeing on question) on specific management of HCV infected AH were:
      routine HCV testing (94%), HCV not changing response to CS (80%) or
      pentoxifylline (91%), no change in approach to treating HCV infected AH (75%).
      None of respondent variables: age, specialty, annual number of patients seen, and
      HCV prevalence could predict respondent to be in consensus on any of or all 4
      questions. Further, only 4% would choose CS for treating HCV infected AH as
      opposed to 47% while treating HCV negative AH. CONCLUSION: Gastroenterologists
      and hepatologists believe that AH patients be routinely checked for HCV. However,
      there is lack of consensus on choice of drug for treatment and outcome of HCV
      positive AH patients. Studies are needed to develop guidelines for management of 
      HCV infected AH patients.
FAU - Singal, Ashwani K
AU  - Singal AK
AD  - Ashwani K Singal, Habeeb Salameh, Anjna Singal, Sarat C Jampana, Daniel H
      Freeman, Karl E Anderson, Don Brunder, Departments of Internal Medicine,
      Gastroenterology, Biostatistics and Library, University of YX Medical Branch,
      Galveston, TX 77555, United States.
FAU - Salameh, Habeeb
AU  - Salameh H
FAU - Singal, Anjna
AU  - Singal A
FAU - Jampana, Sarat C
AU  - Jampana SC
FAU - Freeman, Daniel H
AU  - Freeman DH
FAU - Anderson, Karl E
AU  - Anderson KE
FAU - Brunder, Don
AU  - Brunder D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastrointest Pharmacol Ther
JT  - World journal of gastrointestinal pharmacology and therapeutics
JID - 101547456
PMC - PMC3644613
OT  - Alcoholic hepatitis
OT  - Alcoholic liver disease
OT  - Hepatitis C virus
OT  - Survey
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013/03/21 00:00 [received]
PHST- 2013/03/28 00:00 [revised]
PHST- 2013/04/10 00:00 [accepted]
PHST- 2013/05/14 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2013/05/15 06:01 [medline]
AID - 10.4292/wjgpt.v4.i2.16 [doi]
PST - ppublish
SO  - World J Gastrointest Pharmacol Ther. 2013 May 6;4(2):16-22. doi: